Previous Chapter Chapter 35: Impact of Inhaled Insulin on the Insulin Market Next Chapter

By: Decision Resources Inc

In: The SAGE Handbook of Healthcare

Chapter 35: Impact of Inhaled Insulin on the Insulin Market

  • Citations
  • Add to My List
  • Text Size

Impact of Inhaled Insulin on the Insulin Market
Impact of inhaled insulin on the insulin market
Introduction

There is considerable need for an insulin delivery system that will eliminate the requirement for multiple daily injections in type 1 and type 2 diabetes patients. Recognition of this need has prompted several companies to begin developing less-invasive methods of insulin administration. The first of these alternative methods is an inhaled formulation of rapid-acting insulin, Pfizer's Exubera, launched in the US market in September 2006. The advent of this technology has the potential to impact the insulin market significantly by adding new players and may change medical practice as barriers to the initiation of insulin therapy are lowered.

This chapter provides an overview of current insulin therapy, including various delivery devices, ...

Looks like you do not have access to this content.

Login

Don’t know how to login?

Click here for free trial login.

Back to Top

Copy and paste the following HTML into your website